跳至主要内容
临床试验/NCT00970450
NCT00970450已完成不适用

The Central Analgesic Effects of Paracetamol on Serotonergic Pathways

University Hospital, Basel, Switzerland1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2009年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
16
试验地点
1
主要终点
Pain

研究概览

简要总结

  1. Introduction

Paracetamol, an analgesic prescribed daily, has been in use for more than 50 years. Surprisingly, its mode of action is still unclear. One postulated mechanism is the reinforcement of descending inhibitory pathways. A recent publication in a human pain model raises the question of whether or not Paracetamol acts according to a central serotonergic mechanism. Unfortunately, the chosen model was unable to differentiate between overall pain, secondary hyperalgesia and allodynia. In particular, secondary hyperalgesia and allodynia are central effects.

The planned study will examine the central analgesic effects of paracetamol on allodynia and hyperalgesia by blocking the central effect by adding tropisetron. It will be based on an internationally accepted model for the initiation of secondary hyperalgesia, which was developed and tested by colleagues in Erlangen. 2. Study work plan

This prospective, randomized, placebo-controlled, double-blinded, cross-over trial in 16 male volunteers will address pain ratings and the area of secondary hyperalgesia/allodynia in a human model of electrically evoked pain and compare four different treatment scenarios:

  • Paracetamol 1 g;
  • Paracetamol, 1 g and Tropisetron 5 mg;
  • Tropisetron, 5 mg; and
  • Saline.

Each volunteer will be allocated to each scenario in a cross-over fashion. Four separate treatment trials, at least two weeks apart, will be performed. Each volunteer will be familiarized with the stimulation procedure prior to participation. 3. Ethical considerations

Informed consent will be obtained from each volunteer. In addition, each volunteer will receive remuneration after participating in the study.

Paracetamol is considered to be a very safe drug in healthy patients. Tropisetron, another safe medication, is routinely used in anaesthetic practice as an antiemetic drug. Headache, flush and liver parameter elevation are very rare side effects of minor importance in our daily clinical work as anaesthetists.

This pain provoking procedure was developed at the University Erlangen Germany. It is a standardized method and has repeatedly received approval by research ethics committees internationally. Furthermore, the investigators applied this model to a recent study in Basel (cf your decision "study protocol 330/07;" unpublished data, analysis and writing in progress). 4. Patient number and timetable

The investigators will examine 16 volunteers and expect the experimental component to last 3 months. The investigators plan to complete this study within one year. 5. Study importance

The mode of action of paracetamol remains unclear. The investigators think that this study will enable them to answer important questions concerning the action of paracetamol. The investigators hope that further understanding of this regularly prescribed drug will help us to better understand the complex mechanisms of pain.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
20 Years 至 35 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy male volunteers
  • 20-35 years of age
  • No known medical disorders
  • BMI 18.5 - 39.9 (kg/m2)

排除标准

  • Known drug allergies (paracetamol, tropisetron)
  • Excessive consumption of tobacco (more than 10 cigarettes a day)
  • Excessive consumption of tea or coffee (more than 5 cups a day)
  • Recreational drug addiction
  • Consumption of any medication on the trial days

研究组 & 干预措施

Paracetamol

Experimental

干预措施: Paracetamol (Drug)

Paracetamol/Tropisetron

Experimental

干预措施: Paracetamol (Drug)

Paracetamol/Tropisetron

Experimental

干预措施: Tropisetron (Drug)

Saline

Placebo Comparator

Proband will receive Saline

干预措施: Placebo (Drug)

Tropisetron

Active Comparator

Proband will receive Tropisetron alone

干预措施: Tropisetron (Drug)

结局指标

主要结局

Pain

时间窗: all 20 minutes up to 180 minutes after starting the experiment

次要结局

未报告次要终点

研究者

发起方
University Hospital, Basel, Switzerland
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验